Renal cell carcinoma: management of advanced disease. J Urol 1999;161:381–6. .
Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999;22:145–54. , , .
et al. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol 2005;48:527–33. , ,
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58:1–14. , , , , .
et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016–26. , ,
et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000;192:1535–44. , ,
Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006;12(7 Pt 2):2353s–8s. .
et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008;31:771–80. , ,
et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; application of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56:148–599. (accepted for publication). , ,
et al. Vaccination with p53 peptide pulsed dendritic cells of patients with advanced breast cancer:report from a phase I study. Cancer Immunol Immunother 2004;53:633–41. , ,
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621–67. , , , , .
Delivery of whole tumor lysate into dendritic cells for cancer vaccination. Methods Mol Biol 2008;423:139–53. , , , .
et al. Antigen loading of dendritic cells with whole tumor cell preparations. J Immunol Methods 2003;277:1–16. , ,
et al. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 2007;56:2003–16. , ,
et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89:1172–9. , ,
et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 2006;55:819–29. , ,
et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125:257–67. , ,
et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007;30:749–61. , ,
et al. Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid 2007;17:53–8. , ,
et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8 + T cells as well as CD4 + CD25 + FoxP3 + regulatory T cells toward an antileukemia response. Leukemia 2008;22:1007–17. , ,
et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14:3098–104. , ,
Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003;21:713–58. , , , .
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth. Cancer Res 2008;68:8456–64. , , , , , .
et al. A Preclinical protocol exploring mRNA-transfected allogeneic monocytes as a potential cancer vaccine. Manuscript in preparation 2009 Jan 1. , ,
Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634–42. , , , , , .
et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998;161:2099–105. , ,
Mechanisms of immune privilege for tumor cells by regulatory cytokines produced by innate and acquired immune cells. Semin Cancer Biol 2002;12:291–300. , , .
et al. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 2004;173:1731–7. , ,
et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001;108:51–62. , ,
et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994;179:1273–83. , ,
et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993;177:1199–204. , ,
Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity 1998;8:591–9. , , , , .
et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A 2000;97:11445–50. , ,
et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003;63:491–7. , ,
et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006;25:417–34. , ,
et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998;8:383–90. , ,
Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007;178:7571–80. , , , , , .
et al. Interleukin-17 expression by breast cancer associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 2008;10:R95. , ,